311 related articles for article (PubMed ID: 27665357)
1. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
[TBL] [Abstract][Full Text] [Related]
2. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
3. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
[TBL] [Abstract][Full Text] [Related]
4. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
Shoskes DA; Barazani Y; Fareed K; Sabanegh E
Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
[TBL] [Abstract][Full Text] [Related]
6. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
[TBL] [Abstract][Full Text] [Related]
7. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
[TBL] [Abstract][Full Text] [Related]
8. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
Park JJ; Park BK
J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
[TBL] [Abstract][Full Text] [Related]
9. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
[TBL] [Abstract][Full Text] [Related]
10. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
[TBL] [Abstract][Full Text] [Related]
11. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
[TBL] [Abstract][Full Text] [Related]
12. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
13. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.
Nougaret S; Robertson N; Golia Pernicka J; Molinari N; Hötker AM; Ehdaie B; Sala E; Hricak H; Vargas HA
Abdom Radiol (NY); 2017 Jul; 42(7):1968-1974. PubMed ID: 28258355
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
15. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Tosun M; Uslu H
Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
[TBL] [Abstract][Full Text] [Related]
17. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
[TBL] [Abstract][Full Text] [Related]
18. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
Seo JW; Shin SJ; Taik Oh Y; Jung DC; Cho NH; Choi YD; Park SY
AJR Am J Roentgenol; 2017 Jul; 209(1):W1-W9. PubMed ID: 28418690
[TBL] [Abstract][Full Text] [Related]
19. Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer.
Matsuoka Y; Ishioka J; Tanaka H; Kimura T; Yoshida S; Saito K; Fujii Y; Kihara K
AJR Am J Roentgenol; 2017 Aug; 209(2):W76-W84. PubMed ID: 28570124
[TBL] [Abstract][Full Text] [Related]
20. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
